Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.

Autor:	Mazagatos, Clara, Mendioroz, Jacobo, Rumayor, Mercedes Belén, Gallardo García, Virtudes, Álvarez Río, Virginia, Cebollada Gracia, Ana Delia, Batalla Rebollo, Noa, Barranco Boada, María Isabel, Pérez‐Martínez, Olaia, Lameiras Azevedo, Ana Sofía, López González‐Coviella, Nieves, Castrillejo, Daniel, Fernández Ibáñez, Ana, Giménez Duran, Jaume, Ramírez Córcoles, Cristina, Ramos Marín, Violeta, Larrauri, Amparo, Monge, Susana, Basile, Luca, García Comas, Luis
Předmět:	RESPIRATORY syncytial virus infections HOSPITAL admission & discharge CHILDREN'S hospitals HUMAN metapneumovirus infection RESPIRATORY infections
Zdroj:	Influenza & Other Respiratory Viruses; May2024, Vol. 18 Issue 5, p1-6, 6p
Abstrakt:	Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.